ImmuPharma plc
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Timothy Paul McCarthy XIV, FCCA, MBA
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1 Bartholomew Close London United Kingdom EC1A 7BL
- IPO Date
- Feb 8, 2017
- Website
- immupharma.co.uk
- Similar Companies
- Business
- ImmuPharma plc is a specialist biopharmaceutical company focused on the discovery and development of peptide-based therapeutics for autoimmune diseases, inflammatory conditions and anti-infectives. The company develops innovative drugs including its lead candidate P140 (also known as Forigerimod or Lupuzor), a first-in-class immune tolerance restorer in late-stage development for systemic lupus erythematosus (SLE) and chronic inflammatory demyelinating polyneuropathy (CIDP); BioAMB, an improved peptide formulation of amphotericin-B for serious fungal infections such as aspergillosis; and BioCin, an enhanced peptide version of vancomycin effective against methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile infections. It also advances a next-generation companion diagnostic for precise identification and monitoring of autoimmune patients, alongside preclinical programs in oncology, ophthalmology, metabolism and additional anti-infectives. Founded in 2000 and headquartered in London, England, ImmuPharma operates primarily in the United Kingdom with research collaborations in France and Switzerland, targeting high-unmet-need patient populations through partnerships with major pharmaceutical firms for commercialization. Recent developments include ongoing advanced discussions with multiple top-ten global pharmaceutical companies for partnering on P140, with several parties signing confidential disclosure agreements and the board anticipating deal completion in 2026 following a methodical evaluation process; extension of warrants in oncology-focused investment Incanthera to March 2025; appointment of a new company secretary in October 2024; and securing a financial position extending into Q4 2026 to support partnership activities.
ImmuPharma focused on securing P140 licensing deal in 2026
ImmuPharma launches regulatory push for Kapiglucagon diabetes drug
ImmuPharma: P140 partnering discussions continue; overwhelming backing for investment round
ImmuPharma shares surge 20% as P140 partnering talks advance
ImmuPharma advances P140 partnering talks as patent progress and new study data strengthen programme
ImmuPharma raises up to £7.5m to accelerate diabetes drug development
ImmuPharma draws interest from major pharma groups for P140 partnership
ImmuPharma rallies as partnership talks progress and end-of-year deal target reaffirmed
ImmuPharma is advancing partnership talks, says cash runway has extended
ImmuPharma appoints veteran fund manager Ketan Patel as independent director
ImmuPharma lights up AIM on a dull week for small-caps
Small cap weekly spotlight: pharma stocks see key progress
ImmuPharma soars 141% on new autoimmune patent filing
ImmuPharma files new patent application for autoimmune therapy
ImmuPharma deepens talks with potential partners following progress on autoimmune platform
ImmuPharma in talks with global partners after scientific progress on autoimmune platform
ImmuPharma up 19% after 'stunning' mechanism of action results
ImmuPharma CEO hails 'stunning results' from mechanism of action study of lead asset
ImmuPharma's P140 platform and oversubscribed fundraise - ICYMI
ImmuPharma hails oversubscribed £2.9m investment round